May. 26 at 8:38 PM
$BCTX
If a DSMB releases a highly positive report indicating that a drug is incredibly safe and highly effective (e.g., passing a major Phase 2 or Phase 3 trial milestone), it increases the asset's value. This success often triggers Big Pharma to approach the smaller biotech company for a buyout to secure the drug before it goes to market. Conversely, a negative DSMB report (indicating poor efficacy or unacceptable toxicity) typically tanks the asset's value and deters buyouts
